© 2021 MJH Life Sciences™ and Pharmacy Times. All rights reserved.
Impact of FDA Approval of Infigratinib on the Field of Cholangiocarcinoma Treatment
Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, discussed the importance of the FDA’s expedited approval process for infigratinib in the treatment of previously treated locally advanced or metastatic cholangiocarcinoma.
Pharmacy Times interviewed Milind Javle, PhD, professor of Gastrointestinal Medical Oncology at the University of Texas MD Anderson Cancer Center, on the phase 2 trial results that led to the US FDA approval of infigratinib (Truseltiq, QED Therapeutics) for the treatment of patients with previously treated locally advanced or metastatic cholangiocarcinoma harboring an FGFR2 fusion or rearrangement.
During this discussion, Javle addressed how the US FDA’s approval of infigratinib for the treatment of previously treated locally advanced or metastatic cholangiocarcinoma may impact treatment options for this patient population and impact the field more broadly.
Related Content:
